Luca Gianni

Luca Gianni's AcademicInfluence.com Rankings

Luca Gianni

Medical

#2253

World Rank

#2662

Historical Rank

Oncology

#126

World Rank

#130

Historical Rank

medical Degrees

Luca Gianni

Philosophy

#6551

World Rank

#9603

Historical Rank

Logic

#3702

World Rank

#4900

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Luca Gianni's Degrees

Doctorate Medicine University of Milan

Why Is Luca Gianni Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Luca Gianni's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. (2005) (4911)
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity (2004) (3334)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) (2895)
Trastuzumab emtansine for HER2-positive advanced breast cancer. (2012) (2725)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. (2012) (1702)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease (2016) (1621)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort (2010) (1096)
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. (2002) (835)
Treatment of HER2-positive breast cancer: current status and future perspectives (2012) (767)
Triple-negative breast cancer: an unmet medical need. (2011) (735)
Triple-negative breast cancer: disease entity or title of convenience? (2010) (724)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (2017) (656)
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. (1994) (648)
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. (2010) (634)
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. (2011) (618)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. (2004) (583)
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. (1995) (570)
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. (2016) (568)
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial (2013) (449)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. (2014) (432)
Anthracycline cardiotoxicity: from bench to bedside. (2008) (420)
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. (2014) (402)
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. (2017) (366)
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. (2008) (358)
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. (2003) (358)
HER2-positive breast cancer (2017) (306)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. (2021) (297)
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. (2002) (294)
Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. (1997) (270)
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study (2005) (251)
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. (2012) (246)
Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. (1982) (225)
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. (2013) (222)
The immune system and response to HER2-targeted treatment in breast cancer. (2014) (221)
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). (2014) (202)
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. (2010) (201)
Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study (2014) (193)
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. (2009) (192)
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs (2021) (189)
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. (2010) (181)
Oxidative destruction of DNA by the adriamycin-iron complex. (1984) (170)
Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. (2005) (169)
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. (2005) (166)
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). (2015) (158)
Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. (1995) (155)
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy (2005) (152)
Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. (2018) (142)
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer (2010) (136)
Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen. (1985) (135)
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level (2004) (131)
Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study (2020) (125)
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes (2007) (124)
Pharmacokinetics and metabolism of anthracyclines. (1993) (122)
Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. (1984) (115)
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. (2015) (115)
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. (2018) (112)
Successful re-treatment with taxol after major hypersensitivity reactions. (1993) (112)
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer (2009) (111)
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer (2018) (109)
Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. (2012) (101)
Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. (2009) (101)
Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma (2016) (100)
Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (99)
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer? (2018) (96)
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours (2014) (95)
Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy (2008) (90)
Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere') (2010) (89)
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial (2018) (89)
Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart (2006) (88)
Targeting TRAIL Agonistic Receptors for Cancer Therapy (2007) (85)
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer (2009) (82)
Optic nerve disturbances: a new form of paclitaxel neurotoxicity. (1994) (81)
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials (2021) (81)
European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF) (2005) (80)
A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. (2013) (77)
Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. (2001) (77)
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer (2017) (76)
Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. (1991) (76)
Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies (2006) (74)
Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. (1990) (74)
Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. (2004) (73)
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. (2014) (71)
Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. (2009) (67)
Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. (2000) (66)
Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients (2000) (66)
New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. (1995) (64)
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. (2015) (64)
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. (2017) (62)
5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976) (2011) (61)
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. (2010) (61)
Bile acid-induced inhibition of the lymphoproliferative response to phytohemagglutinin and pokeweed mitogen: An in vitro study (1980) (59)
Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group. (1986) (58)
International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). (2011) (57)
Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). (2013) (56)
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. (2003) (56)
Thiol-dependent DNA damage produced by anthracycline-iron complexes. The structure-activity relationships and molecular mechanisms. (1985) (56)
Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma (2008) (55)
Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. (2003) (55)
Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. (2003) (55)
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. (2010) (54)
LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC) (2020) (53)
The role of taxanes in the treatment of breast cancer. (1996) (53)
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers (2013) (53)
Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. (1997) (51)
Role of iron in adriamycin biochemistry. (1986) (51)
Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis (1998) (51)
Role of anthracyclines in the treatment of early breast cancer. (2009) (51)
Future options with trastuzumab for primary systemic and adjuvant therapy. (2004) (48)
Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer (2015) (47)
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. (2010) (46)
Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG) (1999) (45)
Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial. (2009) (45)
Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma (2017) (45)
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. (2018) (44)
Hallmarks of triple negative breast cancer emerging at last? (2014) (44)
S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC) (2011) (44)
Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. (2019) (43)
Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis (2007) (43)
Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (42)
Role of daunosamine and hydroxyacetyl side chain in reaction with iron and lipid peroxidation by anthracyclines. (1988) (42)
Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. (2017) (42)
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer (2014) (42)
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). (2019) (41)
LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial (2020) (41)
Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies (2007) (40)
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. (2018) (40)
Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. (1994) (39)
Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab. (2018) (39)
[Breast cancer in the early stage]. (2012) (39)
Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). (2015) (38)
Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2 (2005) (37)
Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. (2001) (37)
A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. (2004) (37)
Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. (2007) (37)
Treatment of AL amyloidosis with 4'-lodo-4'-deoxydoxorubicin: an update. (1999) (35)
Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies (2018) (35)
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. (2013) (34)
Anthracycline resistance: the problem and its current definition. (1997) (33)
Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. (2006) (32)
Adjuvant and neoadjuvant treatment of breast cancer. (2001) (31)
New Drug Therapy of Amyloidoses: Resorption of AL-Type Deposits With (2016) (30)
A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). (2010) (29)
Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer (2017) (28)
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. (2007) (28)
Drug Interactions of Paclitaxel and Docetaxel and their Relevance for the Design of Combination Therapy (2001) (28)
Long‐term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ‐cell tumours (2009) (28)
2030 ORAL Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) Phase III trial (2007) (28)
Ixabepilone and the narrow path to developing new cytotoxic drugs. (2007) (27)
A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer (2008) (27)
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma (2016) (27)
Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist. (2013) (26)
Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). (2014) (26)
Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies. (2015) (26)
The Future of Targeted Therapy: Combining Novel Agents (2002) (25)
Modified cisplatin, etoposide (or vinblastine) and ifosfamide salvage therapy for male germ-cell tumors. Long-term results. (1992) (25)
The "other" signaling of trastuzumab: antibodies are immunocompetent drugs. (2008) (24)
Bile acid-induced inhibition of the lymphoproliferative response to phytohemagglutinin and pokeweed mitogen: an in vitro study. (1980) (24)
Experience at the Istituto Nazionale Tumori with paclitaxel in combination with doxorubicin in women with untreated breast cancer. (1997) (24)
Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3. (2015) (24)
IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC). (2016) (23)
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. (2012) (22)
A Double-blind, Randomized Phase lib Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared to Placebo (PL) When Administered in Combination with Docetaxel And/or Letrozole in Patients with Metastatic Breast Cancer (MBC): FM-B07-01 Trial (2011) (21)
Cardiotoxic effects of anthracycline–taxane combinations (2003) (21)
Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab (2008) (21)
Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice (2004) (21)
Anthracyclines and early breast cancer: the end of an era? (2009) (20)
Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer. (2013) (20)
Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). (2020) (20)
Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation. (2009) (20)
Theoretical and practical aspects of paclitaxel scheduling. (1995) (19)
PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review (2019) (19)
Technology Insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer (2004) (19)
Report on the International Colloquium on Cardio-Oncology (Rome, 12–14 March 2014) (2014) (19)
The choice of the correct imaging modality in breast cancer management (2004) (19)
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer (2021) (19)
Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC) (2008) (19)
Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data (2005) (18)
Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. (2009) (18)
ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study. (2016) (17)
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection (2015) (17)
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors (2014) (17)
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors (2013) (16)
Monoclonal antibodies against doxorubicin (1988) (16)
Evaluation of Everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway : exploratory biomarker observations from the BOLERO-3 trial (2013) (16)
Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans. (1983) (15)
Evaluation of three advanced methodologies, COLD-PCR, microarray and ddPCR, for identifying the mutational status by liquid biopsies in metastatic colorectal cancer patients. (2019) (15)
Adjuvant trastuzumab in early breast cancer. (2006) (15)
Maintenance with everolimus (RAD001) and trastuzumab (T) after discontinuation of chemotherapy in patients (pts) with heavily pretreated HER2-positive metastatic breast cancer (MBC): Pooled data of extension cohorts of phase Ib/II studies. (2010) (14)
PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). (2017) (14)
Biweekly paclitaxel and cisplatin in patients with advanced head and neck carcinoma. A phase II trial. (1997) (14)
Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): an exploratory evaluation (2008) (13)
Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients (2015) (13)
ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL (2012) (13)
Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples (2014) (13)
Impact of nodal status on indication for adjuvant treatment in clinically node negative breast cancer. Istituto Nazionale per lo Studio e las Cura dei Tumori. (2000) (13)
1802 Overall survival (OS) from the phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) signaling inhibitor, in AR+ advanced triple-negative breast cancer (aTNBC) (2015) (12)
Hera Trial: 2 Years Versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with Her2-Positive Early Breast Cancer at 8 Years of Median Follow up (2012) (12)
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas (2018) (12)
Paclitaxel plus doxorubicin in metastatic breast Ca: the Milan experience. (1998) (11)
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study (2021) (11)
Future directions of paclitaxel-based therapy of breast cancer. (1997) (11)
Tolerability in patients receiving trastuzumab with or without chemotherapy. (2001) (11)
Breast cancer: Nuclear medicine in diagnosis and therapeutic options (2008) (11)
A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors (2008) (11)
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. (2021) (11)
Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). (2015) (11)
Abstract GS1-00: Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial (2022) (11)
High-dose chemotherapy for breast cancer: any use for it? (2002) (10)
Anthracycline cardiotoxicity. (2008) (10)
Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy. (2017) (10)
Activity and toxicity of 4'-iodo-4'-deoxydoxorubicin in patients with advanced breast cancer. (1991) (10)
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience (2015) (9)
Breast cancer: diagnostic and therapeutic options (2004) (9)
Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer. (2012) (9)
Putting taxanes to work in operable breast cancer: a search for selective indications from empirical studies. (1998) (9)
Stereoselectivity of iododoxorubicin reduction in various animal species and humans. (1993) (9)
Microarray Approach Combined with ddPCR: An Useful Pipeline for the Detection and Quantification of Circulating Tumour DNA Mutations (2019) (9)
Relationship between HER 2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM 4450 g : a randomized phase II study of patients with previously untreated HER 2-positive metastatic breast cancer (2014) (8)
S1-7: Molecular Tumor Characteristics Influence Adjuvant Endocrine Treatment Outcome. (2011) (8)
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. (2018) (8)
A phase II trial of the novel oral camptothecin gimatecan (G) in women with anthracycline (A) and taxane (T) pre-treated advanced breast cancer. (2006) (8)
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis (2022) (7)
5004 Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab (2009) (7)
Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC) (2008) (7)
Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies. (2018) (7)
EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen. (2011) (7)
Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer. (2019) (7)
P301 Addition of pertuzumab (P) to trastuzumab (H)-based neoadjuvant chemotherapy significantly improves pathological complete response in women with HER2-positive early breast cancer: Result of a randomised phase II study (NEOSPHERE) (2011) (6)
436 Trastuzumab- (H) and everolimus- (RAD001) containing regimens are safe and active when reintroduced in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) pre-treated with lapatinib (2010) (6)
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer (2022) (6)
Timing of Surgery and the Role of Cytoreductive Chemotherapy in Patients with Advanced Ovarian Carcinoma (1988) (6)
Maintenance With Everolimus (RAD001) and Trastuzumab After Discontinuation of Chemotherapy in Heavily Pretreated HER-2+Metastatic Breast Cancer Patients: Pooled Data of Extension Cohorts of Phase Ib/II Studies (2010) (6)
Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer (2008) (6)
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma (2020) (6)
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. (2022) (6)
Introducing new molecular technologies into routine clinical cancer care: is there an impact on the treatment of breast cancer? (2008) (6)
Cardiac safety and antitumor activity of doxorubicin and taxol followed by weekly taxol (AT&T) when herceptin is initiated with AT or with T alone in women with HER2-positive advanced breast cancer (2001) (5)
A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer. (2012) (5)
Pathological complete response in breast cancer – Authors' reply (2015) (5)
The role of doxorubicin-iron complex in superoxide production and membrane damage (1981) (5)
The relevance of pharmacology in clinical oncology practice. Pharmacology is relevant. (1993) (5)
Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program. (2009) (5)
Phase 1b study defining the optimal dosing combinations of the mTOR inhibitor AP23573 and Paclitaxel (PTX) (2007) (5)
Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane (2021) (5)
A phase I trial of antifibronecitin 131I-L19-small immunoprotein (L19-SIP) in solid tumors and lymphoproliferative disease (2008) (5)
Combination of paclitaxel and two schedules of gefitinib in patients with metastatic breast cancer. (2006) (5)
Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study. (2019) (5)
Everolimus (Afinitor®), Trastuzumab (H), and Paclitaxel (P) or Vinorelbine (V) in the Treatment of HER-2+ Metastatic Breast Cancer (MBC) Patients (Pts) Pre-Treated with Lapatinib-Containing Therapy: Pooled Analysis of 2 Phase I Studies. (2009) (5)
First-in-human phase I study of CetuGEX, a novel anti-EGFR monoclonal antibody (mAb) with optimized glycosylation and antibody dependent cellular cytotoxicity. (2013) (5)
Surrogate markers for targeted therapy-based treatment activity and efficacy. (2011) (4)
Abstract P2-15-03: Cardiac safety of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (EBC): Final data from TDM4874g (2013) (4)
The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine. (2016) (4)
Never use anthracyclines with trastuzumab: it is time to reconsider the taboo (2009) (4)
Handbook of HER2-Targeted Agents in Breast Cancer. (2014) (4)
Abstract PS11-09: Impact ofUGT1A1status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer (2021) (4)
Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC) (2012) (4)
Abstract OT3-2-01: A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer (2013) (4)
Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study. (2022) (4)
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer (2022) (4)
Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement (2021) (4)
Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial. (2020) (4)
Subtype-Speci fi c Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer (2015) (4)
An unmet need: tailoring extended adjuvant endocrine therapy (2013) (4)
Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer (2022) (4)
Abstract CT014: A large phase I study of TAS-114 in combination with S-1 in patients with advanced solid tumors (2018) (4)
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (4)
Abstract CT205: A phase I dose-escalation study of trametinib (T) in combination with continuous or intermittent GSK2126458 (GSK458) in patients (pts) with advanced solid tumors (2014) (4)
A dendritic metagene that predicts prognosis and endocrine resistance in breast cancer. (2012) (4)
The cost of life: should it matter to doctors? (2006) (3)
Abstract P1-18-01: Risk of recurrence and death in patients with early HER2-positive breast cancer who achieve a pathological complete response (pCR) after different types of HER2-targeted therapy: A retrospective exploratory analysis (2020) (3)
New active drugs in the treatment of lymphomas (1994) (3)
Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation (2020) (3)
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial (2021) (3)
Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial. (2013) (3)
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer (2021) (3)
Effect of DNA hypermethylation on immune escape through downregulation of antigen presentation genes in breast cancer. (2016) (3)
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. (2022) (3)
Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial. (2013) (3)
A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer. (2014) (3)
Phase I study with antifibronectin I-131 L19-SIP: First dosimetric and therapeutic results (2007) (3)
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab. (2022) (3)
Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study. (2006) (3)
Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma (2016) (3)
Abstract OT2-01-07: A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) (2017) (3)
Can tamoxifen relieve motion sickness? (2005) (3)
Phase l study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration. (2010) (3)
Targeting the epidermal growth factor receptor a new strategy in cancer treatment. (2002) (3)
Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial (2022) (3)
Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. (2020) (2)
Cisplatin and Cyclophosphamide in Advanced Ovarian Carcinoma: Activity and Toxicity of an Ambulatory Regimen (1990) (2)
Learning from Cl-941 about pharmacokinetically guided dose escalation. (1992) (2)
First report of the European Cooperative Trial in Operable Breast Cancer II (ECTO II): Effects of primary chemo-endocrine therapy on local-regional disease in ER-positive breast cancer (2008) (2)
Phase I clinical trial of namitecan (ST1968): Results with D1-3 q3wks schedule. (2011) (2)
386 Phase I study of the vascular disrupting agent (VDA) ombrabulin (Ob) in combination with taxanes (T) and platinum salts (PS) in patients (pts) with advanced solid tumors (2010) (2)
B01*A randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: the ghost regimen strikes back (2016) (2)
ER + /HER2+ and ER-/Her2+ Breast Cancers are Molecularly Distinct but Immune Gene Signatures are Prognostic and Predictive in Both Groups (2012) (2)
Is there room for another HER2-targeting drug? (2018) (2)
BOLERO-3 results: pharmacological activity or pharmacokinetic effect?--authors' reply. (2014) (2)
711PPHASE IB TRIAL OF NAB-PACLITAXEL PLUS GEMCITABINE, CAPECITABINE, AND CISPLATIN (PAXG REGIMEN) IN PATIENTS WITH STAGE III PANCREATIC ADENOCARCINOMA. (2014) (2)
Stage-modi ¢ ed international prognostic index e ¡ ectively predicts clinical outcome of localized primary gastric di ¡ use large B-cell lymphoma (1999) (2)
Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). (2021) (2)
Phase Ib clinical and pharmacological study of multiple schedules of pazopanib (P) and epirubicin (EPI) in patients with advanced solid tumors. (2010) (2)
Investigation of molecular targets for therapy in salivary glands carcinoma (2001) (2)
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis (2022) (2)
Role of dose in the treatment of breast cancer. (2004) (2)
Exploratory Analysis of the Relationship Between Her2 Expression (BY QRT-PCR) and Efficacy with First-Line Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (HT) in a Randomized Phase 2 Study of Patients (PTS) with HER2-Positive MBC (2012) (2)
The above letter was referred to the authors who respond as follows (1994) (2)
Assessing the Quality of Life of Patients in Cancer Clinical Trials: Common Problems and Common Sense Solutions (1992) (2)
Assessing the Quality of Life of Patients in Cancer Clinical Trials: Common Problems and Common Sense Solutions (1992) (2)
Dose-adjusting epirubicin in patients with altered liver function: when classical pharmacology makes good practical sense. (2003) (2)
Radioimmunotherapy (RIT) with 131l-L19SIP in solid cancers (SC) and lymphoproliferative diseases: Final results of the first human trial. (2010) (2)
1257 POSTER Phase I Safety and Tolerability Study of Olaparib (AZD2281) in Combination With Liposomal Doxorubicin (PLD) in Patients With Advanced Metastatic Solid Tumours (2011) (1)
Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO). (2013) (1)
Prospective correlative study of FDG-PET SUV and proteomic profile (VeriStrat) of non-small cell lung cancer patients treated with erlotinib. (2012) (1)
Clinical and Pharmacokinetic Study of Ixabepilone (IXA) Plus Epirubicin (EPI) as Therapy for Women with Advanced Breast Cancer (BC). (2009) (1)
Neoadjuvant immunotherapy in TNBC: lesson learnt, remaining questions. (2022) (1)
Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP). (2013) (1)
Abstract P4-04-04: Triple-negative (TN) and HER2+ breast cancers (BC) have different immune milieu in primary and metastatic tumors (2016) (1)
Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment (2008) (1)
Abstract P5-06-02: Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC) (2020) (1)
Anthracycline-based sequential adjuvant chemotherapy in operable breast cancer: Five-year results of a randomized study by the Michelangelo Foundation (2007) (1)
An open-label, multinational, multicentre, phase IIIB umbrella study of subcutaneous trastuzumab with or without chemotherapy or pertuzumab in patients with HER2-positive early or metastatic breast cancer (UmbHER1): Interim safety results from early breast cancer studies (2016) (1)
Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. (2019) (1)
The GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. (2018) (1)
42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC) (2021) (1)
Reply to S.M. Ali et al (2009) (1)
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers (2013) (1)
New challenges in the medical treatment of breast cancer (1998) (1)
Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM). (2016) (1)
Vindesine (VDS) in Padua and Milan (1981) (1)
HER2-directed T-cell receptor-mimicking antibody: a "Me Too" or an example of novel antitumor aggressive mimicry? (2013) (1)
Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC). (2018) (1)
Abstract PD10-09: Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment (2022) (1)
Surgical aspect in NOAH Phase III trial (neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer) (2008) (1)
Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer (2014) (1)
ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial. (2021) (1)
Phase Ib study of RAD001 (R) with pegylated-liposomal doxorubicin (PLD) in patients with advanced solid tumors. (2010) (1)
Scintigraphic imaging and turnover studies with (131) I-serum amyloid P component (SAP) in systemic amyloidosis (1999) (1)
Residual disease after HER2-directed therapies in the neosphere study: Modulation of tumor lymphocyte infiltration (TIL) and prognosis. (2016) (1)
Luca Gianni (2010) (1)
Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial (2019) (0)
Protection of adjuvant trastuzumab in sites of early relapses. (2011) (0)
Phase I dose-finding study of trabectedin (T) in combination with cisplatin (C) in patients (pts) with advanced solid tumors. (2011) (0)
Internat ional Expert Panel on the Use of Pr imary ( Preoperat i ve ) Systemic Treatment of Operable Breast Cancer : Rev iew and Recommendat ions (2003) (0)
Introduction and Background Biology (2013) (0)
Cross-platform performance of genes predictive of pathologic response to doxorubicin-paclitaxel containing regimens (2008) (0)
Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
Use of 4'-iodo - 4 - deoxydoxorubicin for treatment of amyloidosis (1994) (0)
Mechanism-Based P harmacokinetic M odel f or P aclitaxel (2001) (0)
Abstract P1-04-02: Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: A secondary analysis of the NeoTRIPaPDL1 trial (2022) (0)
780 POTENTIAL RELATIONSHIP BETWEEN MITOCHONDRIAL FERRITIN EXPRESSION AND CARDIOTOXICITY IN PATIENTS UNDERGOING ANTHRACYLINE CHEMOTHERAPY (2022) (0)
Pertuzumab – a HER-2 Dimerisation Inhibitor – for the Treatment of Breast and Other Cancers (2011) (0)
International E xpert P anel o n t he U se o f P rimary (Preoperative) S ystemic T reatment o f O perable B reast C ancer: Review a nd R ecommendations (2003) (0)
Faculty Opinions recommendation of Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. (2017) (0)
Outcome prediction in estrogen-receptor positive, chemotherapy- and tamoxifen-treated patients with locally advanced breast cancer (2008) (0)
Demethylating agents to upregulate HLAs and antigen presenting machinery (APM) related genes in HER2+ breast cancer (BC) cell lines. (2018) (0)
Pharmacodynamics of sorafenib: An exploratory assessment of circulating biomarkers in a phase II metastatic breast cancer trial (2007) (0)
[Adjuvant chemotherapy in breast cancer. New strategies]. (2000) (0)
Clinical a nd P harmacologic S tudy o f t he E pirubicin a nd Paclitaxel C ombination i n W omen W ith M etastatic Breast C ancer (2001) (0)
State of the art of adjuvant therapy (2008) (0)
The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors. (2018) (0)
Abstract 3940: Baseline molecular markers and risk of distant relapse in the NeoSphere study (2016) (0)
Phase I study of anti fibronectin 131I-L19-small immunoprotein (SIP): Preliminary dosimetric, pharmacokinetics (PK) and therapeutic results (2007) (0)
S30 Putting the taxanes to work (1998) (0)
PC.01.6 A MULTIDISCIPLINARY APPROACH TO FAMILIAL PANCREATIC CANCER ENRICHES THE PROPORTION OF PATIENTS WITH GENETICALLY CONFIRMED PANCREATIC CANCER SUSCEPTIBILITY (2018) (0)
[Determination of blood glutamic oxalacetic & glutamic pyruvic transaminases in the evaluation of myocardial damage during diphtheric infection]. (1958) (0)
512 POSTER Interim results from a Phase 1/2 study of volociximab in combination with liposomal doxorubicin in patients with advanced epithelial ovarian or primary peritoneal carcinoma that relapsed after platinum/taxane chemotherapy (2008) (0)
Chemioterapia Adiuvante Del Carcinoma Mammario Nuove Acquisizioni (2000) (0)
An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer. (2014) (0)
Pharmacokinetic study of paclitaxel and gefitinib in combination. (2006) (0)
Abstract P2-12-08: Sorafenib for treatment of breast-cancer related lymphedema (2012) (0)
Abstract P4-14-01: Modulation of tumor infiltrating lymphocytes (TILs) by palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ patients (pts) enrolled in the Michelangelo NA-PHER2 trial (2020) (0)
Abstract PD5-05: Clinical implication of tumor infiltrating lymphocytes (TILs) in the ETNA study (2020) (0)
A multidisciplinary approach to familial pancreatic cancer enriches the proportion of patients with genetically confirmed pancreatic cancer susceptibility (2018) (0)
[Importance of some functional and pharmacodynamic stimuli on evaluation of the changes in the repolarization wave of the electrocardiogram noticeable during infectious disease]. (1958) (0)
A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors. (2013) (0)
Activation of protein kinase C in intact human platelets by anthracycline-iron complexes (1987) (0)
Challenging the dogma on trastuzumab: a matter of the heart (2010) (0)
Impact of lactate dehydrogenase (LDH) and absolute lymphocyte count (ALC) on outcome of previously treated patients with malignant pleural mesothelioma (MPM) receiving chemotherapy (CT) with or without NGR-hTNF in the phase 3 trial NGR015. (2016) (0)
359 Paclitaxel by 3-H on day 1 & 8 every three-weeks in women with anthracycline-resistant metastatic breast cancer (1995) (0)
Genekspressionsmarkører for prediction of response to chemotherapy (2005) (0)
136TiP IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC (2016) (0)
Abstract P2-03-05: The heterogeneous clinical behavior of luminal breast cancers is associated with different mutational landscapes (2015) (0)
Procede de reduction de la toxicite de chimiotherapies combinees (2001) (0)
326 POSTER Dose-finding study of pegylated liposomal doxorubicin (PLD) and the mTOR inhibitor RAD001 (R) in patients (pts) with advanced solid tumors (2008) (0)
Taxol: The first taxane anticancer graft (1993) (0)
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer (2022) (0)
5023 Ixabepilone/epiribicin combination as therapy for metastatic breast cancer – a phase Ib study (2009) (0)
Correlations for tested doses and toxicities between first-in-human trials and registration trials of FDA-approved monoclonal antibodies (2016) (0)
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. (2023) (0)
New agents for the treatment of breast cancer (2006) (0)
Breast cancer 2 HER 2-positive breast cancer (2016) (0)
Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial. (2018) (0)
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy. (2023) (0)
Cardiovascular Toxicity of Antitumor Drugs: Translating Molecular Mechanisms into Clinical Facts (2010) (0)
Tumour vessels and vessel formation as therapeutic target (2002) (0)
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. (2023) (0)
Breast conserving surgery in locally advanced breast cancer treated with primary chemotherapy: experience at Istituto Nazionale Tumori (2008) (0)
Four-drug sequential regimen in advanced breast cancer (1987) (0)
Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) (2022) (0)
138P Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for HER2-positive breast cancer (BC) (2021) (0)
Abstract ED11-2: HER2 positive breast cancer (2023) (0)
5142 European Cooperative Trial in Operable Breast Cancer II (ECTO II): activity of primary chemotherapy in ER negative early breast cancer (2009) (0)
New Research on HER2-Positive Breast Cancer (2011) (0)
Abstract P4-05-09: Molecular differences between high and low tumor mutational burden (TMB) across breast cancer (BC) subtypes (2020) (0)
Adjuvant chemotherapy for operable breast cancer: old vs new schema (2005) (0)
P3-16-08: A Phase 2, Randomized Open-Label Study of Iniparib, Administered Either Weekly or Twice-Weekly in Combination with Gemcitabine Plus Carboplatin in Patients with mTNBC. (2011) (0)
[Control and prevention of cardiac damage from antitumor drugs and radiation]. (1989) (0)
Chenodeoxycholic acid (CDC) induced inhibition of lymphoproliferative response to mitogens (1977) (0)
Taxane-containing primary chemotherapy for inflammatory breast cancer: INT experience (2008) (0)
A randomized phase 2 trail of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: the ghost regimen strikes back (2017) (0)
14 Combined targeted agents with cytotoxic chemotherapy (2004) (0)
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis (2022) (0)
PD09-04: A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of the PI3-Kinase Inhibitor GDC-0941 in Combination with Paclitaxel and Bevacizumab in Patients with Locally Recurrent or Metastatic Breast Cancer. (2011) (0)
Author Correction: Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation (2021) (0)
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (2022) (0)
Abstract P5-06-21: Prognostic and predictive value of PML in the ETNA study and the TCGA (2020) (0)
Contribution of immune system and tumor-related interferon signaling to epirubicin response in triple-negative (TN) breast cancers. (2015) (0)
A randomized phase II trial on neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma (2018) (0)
OC.13.1 ASSOCIATION OF GERMLINE GENE MUTATIONS IN EARLY ONSET GASTROINTESTINAL CANCERS WITH NEGATIVE FAMILY HISTORY (2018) (0)
EP-1459 Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer (2019) (0)
504PDTHREE OR SIX MONTHS OF ADJUVANT CHEMOTHERAPY FOR COLON CANCER: COMPLIANCE AND SAFETY OF THE PHASE III ITALIAN TOSCA TRIAL. (2014) (0)
ression Patterns in Different Subtypes of Breast Cancer (2010) (0)
Clinical impact of pathological axillary downstaging in locally advanced breast cancer after primary systemic chemotherapy. (2009) (0)
Marchetto da Padova e la scuola capitolare di Cividale. Un documento inedito del 1317 conservato a Udine (1999) (0)
PD-0467: Adaptive, preoperative radiotherapy with image guided Tomotherapy concomitant with chemotherapy in rectal cancer (2015) (0)
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer (2017) (0)
PD-0465: MRI may replace FDG-PET/CT for selective lymph node irradiation in NSCLC radiotherapy: results of a meta-analysis (2010) (0)
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI). (2016) (0)
P3.02b-009 Plasma and Tissue Inflammatory and Angiogenic Biomarkers to Explore Resistance to EGFR-TKIs and Association with VeriStrat Status: Topic: EGFR Biomarkers (2017) (0)
L03.03PHASE I CLINICAL AND PHARMACOLOGICAL STUDY OF CETUGEX, A NOVEL ANTI-EGFR MONOCLONAL ANTIBODY WITH AN OPTIMIZED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (2013) (0)
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. (2022) (0)
study cohortadjuvant CMF in operable breast cancer : 30 years ' follow up of randomised studies of (2005) (0)
Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in metastatic pancreatic adenocarcinoma. (2017) (0)
Cancer esearch or and Stem Cell Biology gnostic and Therapeutic Implications of Distinct Kinase R ression Patterns in Different Subtypes of Breast Cancer (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Luca Gianni?

Luca Gianni is affiliated with the following schools:

Université libre de Bruxelles
Tampere University
University of Milan
Autonomous University of Barcelona
University of Oxford
University of Modena and Reggio Emilia
University of Edinburgh
Okayama University

Luca Gianni's Academic­Influence.com Rankings

Luca Gianni's Degrees

Why Is Luca Gianni Influential?

Luca Gianni's Published Works

Published Works

What Schools Are Affiliated With Luca Gianni?

Luca Gianni's AcademicInfluence.com Rankings